Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
218.66B
Market cap218.66B
Price-Earnings ratio
11.64
Price-Earnings ratio11.64
Dividend yield
2.48%
Dividend yield2.48%
Average volume
13.12M
Average volume13.12M
High today
$49.64
High today$49.64
Low today
$48.41
Low today$48.41
Open price
$48.74
Open price$48.74
Volume
3.23M
Volume3.23M
52 Week high
$71.80
52 Week high$71.80
52 Week low
$35.12
52 Week low$35.12

NVO News

TipRanks 6h
Novo Nordisk announces updated semaglutide label in Singapore

Novo Nordisk (NVO) announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy injection, incorporating clinical evidence from t...

Nasdaq 17h
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Key Points Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver...

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Investor's Business Daily 22h
Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone 4:30 AM ET Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assig...

Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Analyst ratings

57%

of 37 ratings
Buy
37.8%
Hold
56.8%
Sell
5.4%

More NVO News

Investor's Business Daily 24h
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone

Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants. 5/26/2026 More than 70% of GLP-1 users in the UBS Evidence Lab survey...

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
TipRanks 1d
Vivani Advances GLP-1 Implant Program With Novo Nordisk

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 2d
Novo Nordisk Updates DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.9%

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Nasdaq 3d
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Key Points Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of ph...

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
The Motley Fool 5d
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Eli Lilly (LLY +1.35%) is a Wall Street darling thanks to its success in the GLP-1 weight-loss market. There's a problem here, however, because weight-loss drug...

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Simply Wall St 5d
Novo Nordisk Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access

Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP...

Novo Nordisk Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access
Simply Wall St 7d
Novo Nordisk Stock Looks Below Fair Value On a 36% Slide

Novo Nordisk stock has had a tough run over the past three years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Fl...

Novo Nordisk Stock Looks Below Fair Value On a 36% Slide

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.